Diagnostic Development CDMO for IVD Companies
Accelerate your diagnostic pipeline from molecular concept to market-ready rapid lateral flow cards and ELISA kits. In technical partnership with Pentavalent Bio Sciences, we provide milestone-guaranteed development, matched antibody pair discovery, and pilot-scale manufacturing.
Structured Milestone-Based CDMO Delivery Model
Clear deliverables, gated go/no-go validation criteria, and transparent milestone invoicing.
Target & Antigen Expression
Recombinant antigen design, codon optimization, bacterial/mammalian expression, and affinity purification.
Monoclonal Antibody Discovery
Hybridoma generation, high-throughput screening, and matched sandwich pair affinity validation.
Assay Formulation & Strip Assembly
Nitrocellulose membrane selection, colloidal gold conjugation, running buffer optimization, and LOD determination.
Pilot Batch & Stability Verification
Accelerated thermal stability testing, clinical serum specificity panel, and tech-transfer documentation package.
Request a CDMO Technical Feasibility Assessment
Share your target analyte, preferred platform (Rapid Test or ELISA), and project timeline under standard mutual NDA.
Project Inquiry Form
Tell us about your diagnostic or R&D requirements
Frequently Asked Questions About Our Diagnostic CDMO
What is the end-to-end timeline for developing a custom lateral flow rapid test?
A standard custom lateral flow assay project progresses through 4 distinct milestones: Phase 1 (Reagent Generation / Screening: 4-6 weeks), Phase 2 (Assay Formulation & Membrane Optimization: 3-4 weeks), Phase 3 (Analytical Sensitivity & Specificity Validation: 3-4 weeks), and Phase 4 (Pilot Batch Assembly & Stability Studies: 4 weeks). Total typical turnaround is 12 to 16 weeks.
How do you structure intellectual property (IP) and data ownership?
All intellectual property, proprietary antibody sequences, cell line master banks, and assay formulations generated under contract belong 100% exclusively to the client upon completion of agreed milestone payments. Comprehensive Non-Disclosure Agreements (NDAs) are executed prior to project kickoff.
Can you develop matched antibody pairs if only a target antigen is provided?
Yes. Our Bangalore hybridoma platform immunizes mice with your target protein or synthetic peptide, screens hundreds of fusion clones, and isolates high-affinity matched pairs specifically evaluated for sandwich lateral flow or ELISA configurations.
Do you support regulatory dossier preparation and transfer to production?
Yes. We provide complete Design History File (DHF) documentation, Standard Operating Procedures (SOPs), Bill of Materials (BOM), stability testing datasets, and transfer assistance for CDSCO, CE-IVD, or FDA 510(k) filings.
